Compound #41 Targets Acute Myelogenous Leukemia by Inhibiting the Wnt/β-catenin Signaling Pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant Wnt/β-catenin signaling is implicated in acute myelogenous leukemia (AML) pathogenesis.
• Targeting the Wnt/β-catenin pathway presents a potential therapeutic avenue for AML.
• Compound #41 is a novel dipeptide-type inhibitor designed to target this pathway.

Purpose of the Study:

• To synthesize and evaluate compound #41 as a Wnt/β-catenin signaling inhibitor.
• To assess the anti-tumor effects of compound #41 on human AML cell lines.
• To investigate the in vivo efficacy of compound #41 in an AML mouse model.

Main Methods:

• Luciferase reporter assays to measure TCF/β-catenin transcriptional activity.
• In vitro studies using AML cell lines (KG1a, MV4;11) including proliferation, cell cycle, and apoptosis assays.
• RNA-sequencing for gene expression analysis and in vivo orthotopic mouse models to assess anti-tumor effects and survival.

Main Results:

• Compound #41 significantly reduced TCF/β-catenin transcriptional activity.
• In vitro, compound #41 inhibited AML cell proliferation, induced apoptosis, and altered expression of key Wnt/β-catenin target genes.
• In vivo, compound #41 suppressed leukemia cell expansion in bone marrow and prolonged survival in mice.

Conclusions:

• Compound #41 effectively suppresses Wnt/β-catenin signaling by reducing CTNNB1 levels.
• Compound #41 demonstrates potent anti-leukemic activity, including apoptosis induction and proliferation inhibition.
• Compound #41 shows promise as a therapeutic agent for AML by targeting the Wnt/β-catenin pathway.